The Study of ICP-248 in Patients With Mature B-cell Malignancies
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination Therapy in Patients With Mature B-cell Malignancies
Beijing InnoCare Pharma Tech Co., Ltd.
191 participants
Mar 9, 2023
INTERVENTIONAL
Conditions
Summary
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination Therapy in Patients with Mature B-cell Malignancies.This study consists of two parts: Part 1 dose-finding period and Part 2 dose expansion period.
Eligibility
Inclusion Criteria19
- Age ≥ 18 and ≤ 80 years.
- One of the following histopathologically and/or flow cytometry-confirmed diseases according to the 2016 World Health Organization (WHO) classification criteria for lymphohematopoietic neoplasms or meeting the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria: Histopathologically and/or flow cytometry-confirmed CLL/SLL; Pathologically confirmed MCL; Pathologically confirmed B-NHL, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), and lymphoplasmacytic lymphoma (LPL).
- Relapsed disease or refractory disease
- For subjects with B-NHL: Patients must have measurable diseasePatients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of ≤ 2 and a life expectancy of ≥ 6 months.
- Adequate hematologic function.
- Patients with basically normal coagulation function.
- Patients with adequate hepatic, renal, pulmonary and cardiac functions.
- CLL/SLL Patients with an absolute lymphocyte count ≥ 50 x 109/L and any lymph nodes ≥ 5 cm in the long diameter or CLL/SLL or B-NHL patients with any lymph nodes ≥ 10 cm in the long diameter will be enrolled in the study after weighing the risks and benefits with the sponsor's MM.
- Female patients of childbearing potential must have a negative blood pregnancy test within 7 days prior to the first dose of the investigational product; patients of childbearing potential (males and females) must agree to use a reliable birth control method (hormonal or barrier method or abstinence) with their partners from signing the ICF until 90 days after the last dose.The last ICP- 248 dose or within one month after the last dose of Orelabrutinib Or within 12 months after the last dose of Rituximab (whichever is longer).
- Subjects are able to communicate with the investigator well and to complete the study as specified in the study.
- Before the trial, the subjects shall understand the nature, significance, possible benefits, inconveniences and potential risks, as well as the study procedures of the trial in detail and voluntarily sign the written Informed Consent Form (ICF).
- Subjects with CLL/SLL must have an indication for treatment as judged by the investigator.
- History of severe bleeding disorder
- Known alcohol or drug dependence.
- Presence of mental disorders or poor compliance.
- Female patients who are pregnant or lactating.
- Unable to swallow tablets or disease significantly affecting gastrointestinal function.
- Hypersensitivity to the active substance or excipients of ICP-248 tablets or Orelabrutinib tablets (only applicable to subjects in cohort G/H/J/K).Severe allergic reaction or intolerance to murine monoclonal antibodies or murine products.
- Invasive mantle cell lymphoma, such as mother cell subtypes, polymorphic subtypes, or Ki-67 proliferation index>50%, must be discussed with the sponsor's medical monitor regarding patient benefits and risks before being included in this study.
Exclusion Criteria15
- Prior malignancy (other than the disease under study) within 2 years before study entryKnown
- Central nervous system involvement by lymphoma/leukemia
- Underlying medical conditions that, in the investigator's opinion, will render the administration of the investigational product hazardous or obscure the interpretation of the safety or efficacy results.
- Prior autologous stem cell transplant (unless ≥ 3 months after transplant); or prior chimeric cell therapy (unless ≥ 3 months after cell infusion).
- Received a BCL-2 inhibitor prior to initial use of the investigational drug and did not achieve disease remission or disease recurrence/progression on treatment; Disease recurrence/progression after stopping or ending BCL-2 inhibitor therapy is acceptable.
- A history of allogeneic stem cell transplantation.
- Anti-cancer therapy within 14 days prior to the first dose of the investigational product
- An interval of less than 5 half-lives from the last dose of a strong CYP3A inhibitor or inducer (chemical agent, traditional Chinese medicine and dietary supplement) to the first dose of the investigational product, or a plan to use concurrently medications, dietary supplements or food (e.g., grapefruit or grapefruit juice) with strong CYP3A inhibitory or inductive effect during study participation.
- Patients who have undergone major organ surgery (excluding aspiration biopsy) or significant trauma within 28 days prior to the first dose of the investigational product, or who require elective surgery during the trial.
- Patients who have received a live attenuated vaccine within 28 days prior to the first dose of the investigational product (except for vaccination to prevent a major public health event).
- Presence of active infection that currently requires intravenous systemic anti-infective therapy.
- Patients with active hepatitis B or C virus infection.
- History of immunodeficiency, including a positive human immunodeficiency virus (HIV) antibody test.
- History of significant cardiovascular disease
- Patients with previous or concomitant central nervous system disordersHistory or current evidence of severe interstitial lung disease.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Eligible patients will receive ICP-248 orally as per the protocol, once daily for every 28 days as one treatment cycle (except for the food effect investigation phase), until progressive disease (PD), intolerable toxicity, withdrawal of consent, loss to follow-up, initiation of other anti-cancer therapy, death, or end of study, whichever occurs first.
Eligible patients will receive ICP-248 orally as specified in the treatment arm.
Eligible patients will receive ICP-248 and Orelabrutinib as specified in the treatment arm.
Eligible patients will receive ICP-248 and Orelabrutinib as specified in the treatment arm.
Eligible patients will receive ICP-248 and Rituximab as specified in the treatment arm.
Eligible patients will receive ICP-248 and Orelabrutinib as specified in the treatment arm.
Eligible patients will receive ICP-248 and Orelabrutinib and Rituximab as specified in the treatment arm.
Locations(22)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05728658